Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:KRNCVE:NDANASDAQ:VIE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRNKarnalyte ResourcesC$0.19+15.6%C$0.13C$0.07▼C$0.20C$9.86M1.5825,954 shs6,000 shsNDANeptune Digital AssetsC$1.36-6.2%C$1.75C$0.23▼C$2.85C$172.68M3.251.04 million shs1.03 million shsVIEViela Bio$53.01$53.01$25.02▼$65.00$2.91B0.431.07 million shsN/AElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRNKarnalyte Resources+15.63%0.00%+117.65%+85.00%-7.50%NDANeptune Digital Assets-6.21%-16.05%-24.86%+28.30%+253.25%VIEViela Bio0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKRNKarnalyte ResourcesN/AN/AN/AN/AN/AN/AN/AN/ANDANeptune Digital Assets1.4187 of 5 stars3.50.00.00.01.51.70.0VIEViela BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRNKarnalyte Resources 0.00N/AN/AN/ANDANeptune Digital Assets 3.00BuyC$3.00120.59% UpsideVIEViela Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BFSA, VIE, KRN, and NDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails1/30/2025NDANeptune Digital AssetsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetC$2.00 ➝ C$3.00(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRNKarnalyte ResourcesN/AN/AC$0.06 per share3.31C$0.10 per shareN/ANDANeptune Digital AssetsC$2.19M78.95C$0.08 per share17.00C$0.60 per share2.26VIEViela Bio$50M58.26N/AN/A$7.14 per share7.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRNKarnalyte Resources-C$1.63M-C$0.03N/A∞N/AN/A-25.87%-18.08%N/ANDANeptune Digital AssetsC$6.09MC$0.0528.35∞N/A278.48%10.37%-3.20%N/AVIEViela Bio-$86.43M-$7.02N/AN/AN/AN/A-33.97%-31.49%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKRNKarnalyte ResourcesN/AN/AN/AN/AN/ANDANeptune Digital AssetsN/AN/AN/AN/AN/AVIEViela BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRNKarnalyte Resources0.182.866.40NDANeptune Digital AssetsN/A54.384.84VIEViela BioN/A19.5119.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRNKarnalyte ResourcesN/ANDANeptune Digital Assets0.13%VIEViela Bio46.98%Insider OwnershipCompanyInsider OwnershipKRNKarnalyte Resources47.90%NDANeptune Digital Assets9.43%VIEViela Bio31.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRNKarnalyte Resources153.28 millionN/ANot OptionableNDANeptune Digital AssetsN/A126.97 millionN/ANot OptionableVIEViela Bio16654.95 millionN/ANot OptionableBFSA, VIE, KRN, and NDA HeadlinesRecent News About These CompaniesBETDAQ app downloadDecember 30, 2024 | bwsmartcities.businessworld.indc vs punjab 2022December 30, 2024 | everythingexperiential.businessworld.inKhelo India Khelo lucky 3 result todayDecember 30, 2024 | bweducation.businessworld.in777 Win SooterDecember 30, 2024 | bwdisrupt.businessworld.inTherapeutic Drug Monitoring in Rheumatology Has Potential but Faces a Host of HurdlesOctober 23, 2024 | medscape.comAnti-CD19 Monoclonal Antibody Shows Positive Results in Myasthenia GravisOctober 16, 2024 | msn.comDmitry Bivol: Biography, record, fights and moreOctober 10, 2024 | espn.comRGNX-Aktie erreicht 52-Wochen-Tief bei 9,28 US-DollarOctober 9, 2024 | de.investing.comRoche takes on Alexion as FDA approves satralizumab in NMOSDSeptember 29, 2024 | pharmaphorum.comREGENXBIO Inc.: REGENXBIO Appoints Mitchell Chan as Chief Financial OfficerSeptember 17, 2024 | finanznachrichten.deREGENXBIO ernennt Mitchell Chan zum neuen CFO in WachstumsphaseSeptember 17, 2024 | de.investing.comRegenxbio Names Mitchell Chan CFOSeptember 17, 2024 | markets.businessinsider.comAstraZeneca spins out biotech to focus on autoimmune candidatesAugust 27, 2024 | pharmaphorum.comComplement Inhibitors Market is Predicted to Exhibit Remarkable Growth During the Study Period (2020-2034) | DelveInsightAugust 21, 2024 | prnewswire.co.ukMinority Stockholder Was Not a Controller Because Plaintiff Did Not Adequately Plead Actual Control of the Company’s Business AffairsAugust 21, 2024 | law.comFactor D Complement Inhibitor Market Will Witness Robust Growth with Emerging Therapies by 2034 | DelveInsightAugust 19, 2024 | finance.yahoo.comLitigation Leaders: Adam Siegel of Freshfields on Four ‘Cs’ of the Firm’s Litigation PracticeAugust 19, 2024 | law.com2024 Fire Awards: Meet this year's Ablaze honoreesAugust 16, 2024 | bizjournals.comAmgen Touts Q2 Growth Bolstered by Horizon Buy, Promising Obesity PipelineAugust 8, 2024 | biospace.comNovel Drug Made of Gold Nanocrystals Appears Safe in Multiple SclerosisApril 22, 2024 | medpagetoday.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketBy Chris Markoch | March 23, 2025View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketMarketBeat Week in Review – 03/17 - 03/21By MarketBeat Staff | March 22, 2025View MarketBeat Week in Review – 03/17 - 03/21MarketBeat Week in Review – 03/24 - 03/28By Chris Markoch | March 29, 2025View MarketBeat Week in Review – 03/24 - 03/28MarketBeat Week in Review – 03/03 - 03/07By MarketBeat Staff | March 8, 2025View MarketBeat Week in Review – 03/03 - 03/07MarketBeat Week in Review – 03/10 - 03/14By MarketBeat Staff | March 15, 2025View MarketBeat Week in Review – 03/10 - 03/14BFSA, VIE, KRN, and NDA Company DescriptionsKarnalyte Resources TSE:KRNC$0.18 +0.03 (+15.63%) As of 04/4/2025 09:30 AM EasternKarnalyte Resources Inc is a development stage company focused on two fertilizer products, potash and nitrogen, to be produced and manufactured in Saskatchewan. It owns the construction ready Wynyard Potash Project, with planned phase 1 production of high grade granular potash, and two subsequent phases. It is also exploring the development of the Proteos Nitrogen Project, which is a proposed small-scale nitrogen fertilizer plant with a nameplate production capacity of approximately 700 metric tonnes per day of ammonia and approximately 1,200 MTPD of urea, and a target customer market of independent fertilizer wholesalers in Central Saskatchewan.Neptune Digital Assets CVE:NDAC$1.36 -0.09 (-6.21%) As of 04/4/2025 03:59 PM EasternNeptune Digital Assets Corp. builds, owns, and operates digital currency infrastructure assets in Canada. The company stakes and lends various digital currencies. It also engages in the Bitcoin mining, node operations, cryptocurrency staking, and decentralized finance (DeFi) tokens, as well as invests in liquidity mining pools. The company was formerly known as Neptune Dash Technologies Corp. and changed its name to Neptune Digital Assets Corp. in December 2020. Neptune Digital Assets Corp. was founded in 2017 and is headquartered in Vancouver, Canada.Viela Bio NASDAQ:VIEViela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/31 - 04/04 Conagra Stock Could Thrive as Tariffs Hit Other Sectors Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
